Inhibition of CaMKK2 reverses age-associated decline in bone mass

Zachary J. Pritchard, Rachel L. Cary, Chang Yang, Deborah V. Novack, Michael J. Voor, Uma Sankar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Decline in bone formation is a major contributing factor to the loss of bone mass associated with aging. We previously showed that the genetic ablation of the tissue-restricted and multifunctional Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) stimulates trabecular bone mass accrual, mainly by promoting anabolic pathways and inhibiting catabolic pathways of bone remodeling. In this study, we investigated whether inhibition of this kinase using its selective cell-permeable inhibitor STO-609 will stimulate bone formation in 32week old male WT mice and reverse age-associated of decline in bone volume and strength. Tri-weekly intraperitoneal injections of saline or STO-609 (10μM) were performed for six weeks followed by metabolic labeling with calcein and alizarin red. New bone formation was assessed by dynamic histomorphometry whereas micro-computed tomography was employed to measure trabecular bone volume, microarchitecture and femoral mid-shaft geometry. Cortical and trabecular bone biomechanical properties were assessed using three-point bending and punch compression methods respectively. Our results reveal that as they progress from 12 to 32weeks of age, WT mice sustain a significant decline in trabecular bone volume, microarchitecture and strength as well as cortical bone strength. However, treatment of the 32week old WT mice with STO-609 stimulated apposition of new bone and completely reversed the age-associated decrease in bone volume, quality, as well as trabecular and cortical bone strength. We also observed that regardless of age, male Camkk2-/- mice possessed significantly elevated trabecular bone volume, microarchitecture and compressive strength as well as cortical bone strength compared to age-matched WT mice, implying that the chronic loss of this kinase attenuates age-associated decline in bone mass. Further, whereas STO-609 treatment and/or the absence of CaMKK2 significantly enhanced the femoral mid-shaft geometry, the mid-shaft cortical wall thickness and material bending stress remained similar among the cohorts, implying that regardless of treatment, the material properties of the bone remain similar. Thus, our cumulative results provide evidence for the pharmacological inhibition of CaMKK2 as a bone anabolic strategy in combating age-associated osteoporosis.

Original languageEnglish (US)
Pages (from-to)120-127
Number of pages8
JournalBone
Volume75
DOIs
StatePublished - Jun 1 2015

Fingerprint

Protein Kinases
Phosphotransferases
Bone and Bones
Osteogenesis
Thigh
Compressive Strength
Calcium-Calmodulin-Dependent Protein Kinases
Bone Remodeling
Intraperitoneal Injections
Osteoporosis
Cancellous Bone
Therapeutics
Tomography
Pharmacology
STO 609
Cortical Bone

Keywords

  • Bone volume
  • Ca/calmodulin (CaM)-dependent protein kinase kinase 2
  • Microarchitecture
  • STO-609
  • Three-point bending
  • Trabecular punch compression

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology
  • Medicine(all)

Cite this

Pritchard, Z. J., Cary, R. L., Yang, C., Novack, D. V., Voor, M. J., & Sankar, U. (2015). Inhibition of CaMKK2 reverses age-associated decline in bone mass. Bone, 75, 120-127. https://doi.org/10.1016/j.bone.2015.01.021

Inhibition of CaMKK2 reverses age-associated decline in bone mass. / Pritchard, Zachary J.; Cary, Rachel L.; Yang, Chang; Novack, Deborah V.; Voor, Michael J.; Sankar, Uma.

In: Bone, Vol. 75, 01.06.2015, p. 120-127.

Research output: Contribution to journalArticle

Pritchard, ZJ, Cary, RL, Yang, C, Novack, DV, Voor, MJ & Sankar, U 2015, 'Inhibition of CaMKK2 reverses age-associated decline in bone mass', Bone, vol. 75, pp. 120-127. https://doi.org/10.1016/j.bone.2015.01.021
Pritchard, Zachary J. ; Cary, Rachel L. ; Yang, Chang ; Novack, Deborah V. ; Voor, Michael J. ; Sankar, Uma. / Inhibition of CaMKK2 reverses age-associated decline in bone mass. In: Bone. 2015 ; Vol. 75. pp. 120-127.
@article{d1d3cb50b12f45a7bef0783641590cd4,
title = "Inhibition of CaMKK2 reverses age-associated decline in bone mass",
abstract = "Decline in bone formation is a major contributing factor to the loss of bone mass associated with aging. We previously showed that the genetic ablation of the tissue-restricted and multifunctional Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) stimulates trabecular bone mass accrual, mainly by promoting anabolic pathways and inhibiting catabolic pathways of bone remodeling. In this study, we investigated whether inhibition of this kinase using its selective cell-permeable inhibitor STO-609 will stimulate bone formation in 32week old male WT mice and reverse age-associated of decline in bone volume and strength. Tri-weekly intraperitoneal injections of saline or STO-609 (10μM) were performed for six weeks followed by metabolic labeling with calcein and alizarin red. New bone formation was assessed by dynamic histomorphometry whereas micro-computed tomography was employed to measure trabecular bone volume, microarchitecture and femoral mid-shaft geometry. Cortical and trabecular bone biomechanical properties were assessed using three-point bending and punch compression methods respectively. Our results reveal that as they progress from 12 to 32weeks of age, WT mice sustain a significant decline in trabecular bone volume, microarchitecture and strength as well as cortical bone strength. However, treatment of the 32week old WT mice with STO-609 stimulated apposition of new bone and completely reversed the age-associated decrease in bone volume, quality, as well as trabecular and cortical bone strength. We also observed that regardless of age, male Camkk2-/- mice possessed significantly elevated trabecular bone volume, microarchitecture and compressive strength as well as cortical bone strength compared to age-matched WT mice, implying that the chronic loss of this kinase attenuates age-associated decline in bone mass. Further, whereas STO-609 treatment and/or the absence of CaMKK2 significantly enhanced the femoral mid-shaft geometry, the mid-shaft cortical wall thickness and material bending stress remained similar among the cohorts, implying that regardless of treatment, the material properties of the bone remain similar. Thus, our cumulative results provide evidence for the pharmacological inhibition of CaMKK2 as a bone anabolic strategy in combating age-associated osteoporosis.",
keywords = "Bone volume, Ca/calmodulin (CaM)-dependent protein kinase kinase 2, Microarchitecture, STO-609, Three-point bending, Trabecular punch compression",
author = "Pritchard, {Zachary J.} and Cary, {Rachel L.} and Chang Yang and Novack, {Deborah V.} and Voor, {Michael J.} and Uma Sankar",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.bone.2015.01.021",
language = "English (US)",
volume = "75",
pages = "120--127",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Inhibition of CaMKK2 reverses age-associated decline in bone mass

AU - Pritchard, Zachary J.

AU - Cary, Rachel L.

AU - Yang, Chang

AU - Novack, Deborah V.

AU - Voor, Michael J.

AU - Sankar, Uma

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Decline in bone formation is a major contributing factor to the loss of bone mass associated with aging. We previously showed that the genetic ablation of the tissue-restricted and multifunctional Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) stimulates trabecular bone mass accrual, mainly by promoting anabolic pathways and inhibiting catabolic pathways of bone remodeling. In this study, we investigated whether inhibition of this kinase using its selective cell-permeable inhibitor STO-609 will stimulate bone formation in 32week old male WT mice and reverse age-associated of decline in bone volume and strength. Tri-weekly intraperitoneal injections of saline or STO-609 (10μM) were performed for six weeks followed by metabolic labeling with calcein and alizarin red. New bone formation was assessed by dynamic histomorphometry whereas micro-computed tomography was employed to measure trabecular bone volume, microarchitecture and femoral mid-shaft geometry. Cortical and trabecular bone biomechanical properties were assessed using three-point bending and punch compression methods respectively. Our results reveal that as they progress from 12 to 32weeks of age, WT mice sustain a significant decline in trabecular bone volume, microarchitecture and strength as well as cortical bone strength. However, treatment of the 32week old WT mice with STO-609 stimulated apposition of new bone and completely reversed the age-associated decrease in bone volume, quality, as well as trabecular and cortical bone strength. We also observed that regardless of age, male Camkk2-/- mice possessed significantly elevated trabecular bone volume, microarchitecture and compressive strength as well as cortical bone strength compared to age-matched WT mice, implying that the chronic loss of this kinase attenuates age-associated decline in bone mass. Further, whereas STO-609 treatment and/or the absence of CaMKK2 significantly enhanced the femoral mid-shaft geometry, the mid-shaft cortical wall thickness and material bending stress remained similar among the cohorts, implying that regardless of treatment, the material properties of the bone remain similar. Thus, our cumulative results provide evidence for the pharmacological inhibition of CaMKK2 as a bone anabolic strategy in combating age-associated osteoporosis.

AB - Decline in bone formation is a major contributing factor to the loss of bone mass associated with aging. We previously showed that the genetic ablation of the tissue-restricted and multifunctional Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) stimulates trabecular bone mass accrual, mainly by promoting anabolic pathways and inhibiting catabolic pathways of bone remodeling. In this study, we investigated whether inhibition of this kinase using its selective cell-permeable inhibitor STO-609 will stimulate bone formation in 32week old male WT mice and reverse age-associated of decline in bone volume and strength. Tri-weekly intraperitoneal injections of saline or STO-609 (10μM) were performed for six weeks followed by metabolic labeling with calcein and alizarin red. New bone formation was assessed by dynamic histomorphometry whereas micro-computed tomography was employed to measure trabecular bone volume, microarchitecture and femoral mid-shaft geometry. Cortical and trabecular bone biomechanical properties were assessed using three-point bending and punch compression methods respectively. Our results reveal that as they progress from 12 to 32weeks of age, WT mice sustain a significant decline in trabecular bone volume, microarchitecture and strength as well as cortical bone strength. However, treatment of the 32week old WT mice with STO-609 stimulated apposition of new bone and completely reversed the age-associated decrease in bone volume, quality, as well as trabecular and cortical bone strength. We also observed that regardless of age, male Camkk2-/- mice possessed significantly elevated trabecular bone volume, microarchitecture and compressive strength as well as cortical bone strength compared to age-matched WT mice, implying that the chronic loss of this kinase attenuates age-associated decline in bone mass. Further, whereas STO-609 treatment and/or the absence of CaMKK2 significantly enhanced the femoral mid-shaft geometry, the mid-shaft cortical wall thickness and material bending stress remained similar among the cohorts, implying that regardless of treatment, the material properties of the bone remain similar. Thus, our cumulative results provide evidence for the pharmacological inhibition of CaMKK2 as a bone anabolic strategy in combating age-associated osteoporosis.

KW - Bone volume

KW - Ca/calmodulin (CaM)-dependent protein kinase kinase 2

KW - Microarchitecture

KW - STO-609

KW - Three-point bending

KW - Trabecular punch compression

UR - http://www.scopus.com/inward/record.url?scp=84923916645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923916645&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2015.01.021

DO - 10.1016/j.bone.2015.01.021

M3 - Article

VL - 75

SP - 120

EP - 127

JO - Bone

JF - Bone

SN - 8756-3282

ER -